Quick Answer
IN8BIO, INC. reported Operating Income Loss of -$19.44 million for the year ending 2025.
- IN8BIO, INC. showed an increase of +36.1% in Operating Income Loss from 2024 to 2025.
- This data is from IN8BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$2.87 million | Q3 2020: -$1.68 million | Q1 2021: -$2.36 million | Q2 2021: -$3.05 million | Q3 2021: -$3.39 million | Q1 2022: -$6.15 million | Q2 2022: -$7.18 million | Q3 2022: -$7.40 million | Q1 2023: -$7.53 million | Q2 2023: -$7.72 million | Q3 2023: -$7.17 million | Q1 2024: -$8.56 million | Q2 2024: -$8.63 million | Q3 2024: -$7.09 million | Q1 2025: -$5.55 million | Q2 2025: -$5.09 million | Q3 2025: -$3.85 million.
- Over the full 6 years of available data (2020 to 2025), IN8BIO, INC.'s Operating Income Loss has declined by 127.2%.
- Historical annual values: Fiscal year 2025: -$19.44 million | Fiscal year 2024: -$30.44 million | Fiscal year 2023: -$30.01 million | Fiscal year 2022: -$28.52 million | Fiscal year 2021: -$14.65 million | Fiscal year 2020: -$8.56 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: